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Introduction
============

A report of a randomized controlled trial (RCT) should convey to the reader, in a transparent manner, why the study was undertaken, and how it was conducted and analyzed. For example, a lack of adequately reported randomization has been associated with bias in estimating the effectiveness of interventions, \[[@B1],[@B2]\]. To assess the strengths and limitations of an RCT, readers need and deserve to know the quality of its methodology.

Despite several decades of educational efforts, RCTs still are not being reported adequately, \[[@B3]-[@B6]\]. For example, a review, \[[@B5]\] of 122 recently published RCTs that evaluated the effectiveness of selective serotonin reuptake inhibitors (SSRI) as first-line management strategy for depression found that only one (0.8%) paper described randomization adequately. Inadequate reporting makes the interpretation of RCTs difficult if not impossible. Moreover, inadequate reporting borders on unethical practice when biased results receive false credibility.

History of CONSORT
==================

In the mid 1990s, two independent initiatives to improve the quality of reports of RCTs led to the publication of the CONSORT statement, \[[@B7]\] which was developed by an international group of clinical trialists, statisticians, epidemiologists and biomedical editors. CONSORT has been supported by a growing number of medical and health care journals, \[[@B8]-[@B11]\] and editorial groups, including the International Committee of Medical Journal Editors, \[[@B12]\] (ICMJE, The Vancouver Group), the Council of Science Editors (CSE), and the World Association of Medical Editors (WAME). CONSORT is also published in Dutch, English, French, German, Japanese, and Spanish. It can be accessed together with other information about the CONSORT group on the Internet, \[[@B13]\].

The CONSORT statement comprises a checklist and flow diagram for reporting an RCT. For convenience, the checklist and diagram together are called simply CONSORT. They are primarily intended for use in writing, reviewing, or evaluating reports of simple two- group parallel RCTs.

Preliminary indications are that the use of CONSORT does indeed help to improve the quality of reports of RCTs, \[[@B14],[@B15]\]. In an evaluation, \[[@B14]\] of 71 published RCTs, in three journals in 1994, allocation concealment was not clearly reported in 61% (n = 43) of the RCTs. Four years later, after these three journals required authors reporting an RCT to use CONSORT, the proportion of papers in which allocation concealment was not clearly reported had dropped to 39% (30 of 77, mean difference = -22%; 95% confidence interval of the difference: -38%, -6%).

The usefulness of CONSORT is enhanced by continuous monitoring of the biomedical literature that permits it to be modified depending on the merits of maintaining, or dropping current items and including new items. For example, when Meinert, \[[@B16]\] observed that the flow diagram did not provide important information about the number of participants who entered each phase of an RCT (i.e., enrollment, treatment allocation, follow-up, and data analysis), the diagram could be modified to accommodate the information. The checklist is similarly flexible.

This iterative process makes the CONSORT statement a continually evolving instrument. While participants in the CONSORT group and their degree of involvement vary over time, members meet regularly to review the need to refine CONSORT. At the 1999 meeting a decision was made to revise the original statement. This report reflects changes determined by consensus of the CONSORT group, partly in response to emerging evidence on the importance of various elements of RCTs.

Revision of the CONSORT statement
=================================

Thirteen members of the CONSORT group met in May 1999 with the primary objective of revising the original CONSORT checklist and flow diagram, as needed. The merits of including each item were discussed by the group in the light of current evidence. As in developing the original CONSORT statement, our intention was to keep only those items deemed fundamental to reporting standards for an RCT. Some items not considered essential may well be highly desirable and should still be included in an RCT report even though they are not included in CONSORT. Such items include institutional ethical review board approval, sources of funding for the trial, and a trial registry number (as, for example, the International Standard Randomized Controlled Trial Number (ISRCTN) used to register the RCT at its inception \[[@B17]\].

Shortly after the meeting a revised version of the checklist was circulated to the group for additional comments and feedback. Revisions to the flow diagram similarly were made. All of these changes were discussed when CONSORT participants met in May 2000 and the revised statement finalized shortly afterwards.

The revised CONSORT statement includes a 22-item checklist (Table [1](#T1){ref-type="table"}) and a flow diagram (Figure [1](#F1){ref-type="fig"}). Its primary aim is helping authors improve the quality of reports of simple two-group parallel RCTs. However, the basic philosophy underlying the development of the statement can be applied to any design. In this regard additional statements for other designs will be forthcoming from the group, \[[@B13]\]. CONSORT can also be used by peer reviewers and editors to identify reports with inadequate description of trials and those with potentially biased results, \[[@B1],[@B2]\].

![Flow Diagram of the progress through the phases of a randomized trial (i.e., enrollment, intervention allocation, follow-up, and data analysis)](1471-2288-1-2-1){#F1}

###### 

Checklist of items to include when reporting a randomized trial

  ***PAPER SECTION***           **Item**   **Descriptor**                                                                                                                                                                                                                                                                                                                                  **Reported**   
  ----------------------------- ---------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- --
  ***TITLE & ABSTRACT***        1          How participants were allocated to interventions (e.g., random allocation\", \"randomized\", or \"randomly assigned\").                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                          
  ***INTRODUCTION***                                                                                                                                                                                                                                                                                                                                                                                      
  **Background**                2          Scientific background and explanation of rationale.                                                                                                                                                                                                                                                                                                            
  ***METHODS***                                                                                                                                                                                                                                                                                                                                                                                           
  **Participants**              3          Eligibility criteria for participants and the settings and locations where the data were collected.                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                          
  **Interventions**             4          Precise details of the interventions intended for each group and how and when they were actually administered.                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                          
  **Objectives**                5          Specific objectives and hypotheses.                                                                                                                                                                                                                                                                                                                            
  **Outcomes**                  6          Clearly defined primary and secondary outcome measures and, when applicable,                                                                                                                                                                                                                                                                                   
                                           any methods used to enhance the quality of measurements (e.g., multiple observations, training of assessors).                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                          
  **Sample size**               7          How sample size was determined and, when applicable, explanation of any interim analyses and stopping rules.                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                          
  **Randomization:**                                                                                                                                                                                                                                                                                                                                                                                      
  **Sequence generation**       8          Method used to generate the random allocation sequence, including details of any restriction (e.g., blocking, stratification).                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                          
  **Allocation concealment**    9          Method used to implement the random allocation sequence (e.g., numbered                                                                                                                                                                                                                                                                                        
                                           containers or central telephone), clarifying whether the sequence was concealed until interventions were assigned.                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                          
  **Implementation**            10         Who generated the allocation sequence, who enrolled participants, and who assigned participants to their groups.                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                          
  **Blinding (Masking)**        11         Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment. If done, how the success of blinding was evaluated.                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                          
  **Statistical methods**       12         Statistical methods used to compare groups for primary outcome(s); Methods for additional analyses, such as subgroup analyses and adjusted analyses.                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                          
  ***RESULTS***                                                                                                                                                                                                                                                                                                                                                                                           
  **Participant flow**          13         Flow of participants through each stage (a diagram is strongly recommended). Specifically, for each group report the numbers of participants randomly assigned, receiving intended treatment, completing the study protocol, and analyzed for the primary outcome. Describe protocol deviations from study as planned, together with reasons.                  
                                                                                                                                                                                                                                                                                                                                                                                                          
  **Recruitment**               14         Dates defining the periods of recruitment and follow-up.                                                                                                                                                                                                                                                                                                       
  **Baseline data**             15         Baseline demographic and clinical characteristics of each group.                                                                                                                                                                                                                                                                                               
  **Numbers analyzed**          16         Number of participants (denominator) in each group included in each analysis and whether the analysis was by intention-to-treat\". State the results in absolute numbers when feasible (e.g., 10/20, not 50%).                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                          
  **Outcomes and Estimation**   17         For each primary and secondary outcome, a summary of results for each group, and the estimated effect size and its precision (e.g., 95% confidence interval).                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                          
  **Ancillary analyses**        18         Address multiplicity by reporting any other analyses performed, including subgroup analyses and adjusted analyses, indicating those pre-specified and those exploratory.                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                          
  **Adverse events**            19         All important adverse events or side effects in each intervention group.                                                                                                                                                                                                                                                                                       
  ***DISCUSSION***                                                                                                                                                                                                                                                                                                                                                                                        
  **Interpretation**            20         Interpretation of the results, taking into account study hypotheses, sources of potential bias or imprecision and the dangers associated with multiplicity of analyses and outcomes.                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                          
  **Generalizability**          21         Generalizability (external validity) of the trial findings.                                                                                                                                                                                                                                                                                                    
  **Overall evidence**          22         General interpretation of the results in the context of current evidence.                                                                                                                                                                                                                                                                                      

During the 1999 meeting the group also discussed the benefits of developing an explanatory document to enhance the use and dissemination of CONSORT. The document is patterned on reporting of statistical aspects of clinical research, \[[@B18]\] which was developed to help facilitate the recommendations of the ICMJEs Uniform Requirements for Manuscripts Submitted to Biomedical Journals. Three members of the CONSORT group (DGA, KFS, DM), with assistance from members on some checklist items, drafted an explanation and elaboration document. That document, \[[@B19]\] was circulated to the group for additions and revisions and was last revised after review at the latest CONSORT group meeting.

Changes to CONSORT
==================

• In the revised checklist a new column for \"paper section and topic\" integrates information from the \"subheading\" column that was contained in the original statement.

• The \"Was it reported?\" column has been integrated into a \"reported on page \#\" column, as requested by some journals.

• Each item of the checklist is now numbered and the syntax and order have been revised to improve the flow of information.

• The \"Title\" and \"Abstract\" are now combined in the first item.

• While the content of the revised checklist is similar to the original one some items that previously were combined are now separate. For example, previously authors were asked to describe \"primary and secondary outcome(s) measure(s) and the minimum important difference(s), and indicate how the target sample size was projected\". In the new version issues pertaining to outcomes (item 6) and sample size (item 7) are separate, enabling authors to be more explicit about each. Moreover, some items request additional information. For example, for outcomes (item 6) authors are asked to report any methods used to enhance the quality of measurements, such as multiple observations.

• The item asking for the unit of randomization (e.g., cluster) has been dropped because specific checklists have been developed for reporting cluster RCTs, \[[@B20]\] and other design types, \[[@B13]\] since publication of the original checklist.

• Whenever possible new evidence is incorporated into the revised checklist. For example, authors are asked to be explicit about whether the analysis reported is by intention-to-treat (item 16). This request is based in part on the observations, \[[@B21]\] that (a) authors do not adequately describe and apply intention-to-treat analysis and (b) reports that do not provide this information are less likely to report other relevant information, such as losses to follow-up, \[[@B22]\].

• The revised flow diagram depicts information from four stages of a trial (enrolment, intervention allocation, follow-up, and analysis). The revised diagram explicitly includes the number of participants, for each intervention group, included in the primary data analysis. Inclusion of these numbers lets the reader know whether the authors have performed an intention to treat analysis, \[[@B21]-[@B23]\]. Because some of the information may not always be known and to accommodate other information, the structure of the flow diagram may need to be modified for a particular trial. Inclusion of the participant flow diagram in the report is strongly recommended but may be unnecessary for simple trials, such as those without any participant withdrawals or dropouts.

Discussion
==========

Specifically developed to provide guidance to authors about how to improve the quality of reporting of simple two-group parallel RCTs, CONSORT encourages transparency when reporting the methods and results so that reports of RCTs can be interpreted both readily and accurately. However, CONSORT does not address other facets of reporting that also require attention, such as scientific content and readability of RCT reports. Some authors in their enthusiasm to use CONSORT have modified the checklist, \[[@B24]\]. We recommend against such modifications because they may be based on a different process than the one used by the CONSORT group.

The use of CONSORT seems to reduce (if not eliminate) inadequate reporting of RCTs \[[@B14],[@B15]\]. Potentially, the use of CONSORT should have a positive influence on how RCTs are conducted. Granting agencies have noted this potential relationship and in at least in one case, \[[@B25]\] have encouraged grantees to consider in their application how they have dealt with the CONSORT items.

The evidence-based approach used to develop CONSORT has also been used to develop standards for reporting meta-analyses of randomized trials, \[[@B26]\], meta-analyses of observational studies, \[[@B27]\] and diagnostic studies (personal communication - Jeroen Lijmer). Health economists have also started to develop reporting standards, \[[@B28]\] to help improve the quality of their reports, \[[@B29]\]. The intent of all of these initiatives is to improve the quality of reporting of biomedical research, \[[@B30]\] and by doing so to bring about more effective health care.

The revised CONSORT statement will replace the original one in those journals and groups that already support it. Journals that do not yet support CONSORT may do so by registering on the CONSORT Internet site, \[[@B13]\]. In order to convey to authors the importance of improved quality in the reporting of RCTs, we encourage supporting journals to reference the revised CONSORT statement and the CONSORT Internet address, \[[@B13]\] in their \"Instructions to Contributors\". As the journals publishing the revised CONSORT statement have waived copyright protection, CONSORT is now widely accessible to the biomedical community. The CONSORT checklist and flow diagram can also be accessed at the CONSORT Internet site, \[[@B13]\].

A lack of clarification of the meaning and rationale for each checklist item in the original CONSORT statement has been remedied with the development of the CONSORT explanation and elaboration document, \[[@B19]\] which can also be found on the CONSORT Internet site, \[[@B13]\]. This document includes reporting the evidence on which the checklist items are based, including the references, which annotated the checklist items in the previous version. We encourage journals to also include reference to this document also in their Instructions to Contributors.

Emphasizing the evolving nature of CONSORT, the CONSORT group invites readers to comment on the updated checklist and flow diagram through the CONSORT Internet site, \[[@B13]\]. Comments and suggestions will be collated and considered at the next meeting of the group in 2001.

Footnote
========

The revised CONSORT statement is also published in JAMA (Moher D, Schulz KF, Altman DG, for the CONSORT group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. JAMA 2001; **285**:1987-1991), The Lancet (Moher D, Schulz KF, Altman DG, for the CONSORT group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials Lancet; 2001; **357**:1191-1194), and Annals of Internal Medicine (Moher D, Schulz KF, Altman DG, for the CONSORT group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. Annals of Internal Medicine; 2001; **134**:657-662). Authors can use any one of these references, as well as the reference in BMC Medical Research Methodology, when citing CONSORT.
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